ATO
Cheaper & Alternative Brands
Same generic (Arsenic Trioxide), same form (IV Infusion)No other brands currently registered with this exact active generic and dosage form.
Clinical Prescribing Information
Medical monograph and safety information for healthcare professionals & patients.Indications & Clinical Uses
ATO is an arsenical indicated:
In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t (15;17) translocation or PML/RAR-alpha gene expression.
For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t (15;17) translocation or PML/RAR-alpha gene expression.
Dosage & Administration
Newly-diagnosed low-risk APL:
Induction
: Administer 0.15 mg/kg/day intravenously daily in combination with tretinoin until bone marrow remission. Do not exceed 60 days.
Consolidation
: Administer 0.15 mg/kg/day intravenously daily for 5 days per week during weeks 1-4 of each 8-week cycle for a total of 4 cycles in combination with tretinoin.
Relapsed or refractory APL:
Induction
: Administer 0.15 mg/kg/day intravenously daily until bone marrow remission. Do not exceed 60 days.
Consolidation
: Administer 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks.
Contraindications
Arsenic Trioxide is contraindicated in patients with hypersensitivity to arsenic.
Side Effects & Adverse Reactions
The most common adverse reactions (>30%) are nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus.
Warnings & Precautions
Hepatotoxicity
: Elevated aspartate aminotransferase (AST), alkaline phosphatase and serum bilirubin have occurred in patients with newly-diagnosed low-risk APL treated with TRISENOX in combination with tretinoin. Monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold TRISENOX for certain elevations in AST, alkaline phosphatase and bilirubin and resume at reduced dose upon resolution.
Carcinogenesis
: ATO is a human carcinogen. Monitor patients for the development of second primary malignancies.
Embryo-Fetal Toxicity
: Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.
Pharmacology & Mechanism of Action
The mechanism of action of Arsenic Trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.